MEDDDICAL has introduced a new Real-World Evidence (RWE) advisory service aimed at supporting biotech companies in navigating the complexities of clinical development.
This advisory service is tailored for pharmaceutical and biotech teams that require enhanced data strategies, predictive analytics, and market access insights as they face shortened development timelines. It focuses on areas such as claims data strategy, synthetic patient cohort analysis, and AI-driven analytics, enabling companies to select credible data sources and evidence-generation methods that align with regulatory and payer requirements.
The launch is timely, coinciding with advancements in AI that have significantly accelerated drug discovery processes. For instance, AI has enabled certain drug candidates to move into clinical trials in a fraction of the typical timeframe. However, this rapid pace also introduces challenges, including regulatory hurdles and the need for robust evidence strategies to support development decisions.
As demand for RWE grows, particularly at the initial stages of projects, MEDDDICAL aims to assist biotech firms in effectively leveraging real-world data. The company emphasizes that while AI can speed up discovery, it simultaneously heightens the necessity for a strong evidence strategy to ensure successful market entry and commercial viability.